EMPHASIS HF

Related by string. * emphasied . emphasis . Emphasis : EMPHASIS HF trial . Emphasis sic . Particular emphasis . POINT OF EMPHASIS . Stroock emphasis . Spiritual Emphasis . Emphasis mine . EMPHASIS . Emphasis ours . EMPHASIS ON . Puts Emphasis / HFD . h f . HFs . Hfd . HFS . hf . Hf . HfS . hfs : frequencies LF HF . HF Gerry Lenfest . OPTIMIZE HF . HF VHF . CCP hf . ASCEND HF . HF RFID tags . HF inlays . HF V2 . MedWatch HF 2 * *

Related by context. Frequent words. (Click for all words.) 60 phase IIa 56 phase IIb 56 tocilizumab 56 prespecified 56 axitinib 55 Phase 2b study 55 Phase 1b clinical 55 QTc 55 placebo controlled randomized 55 COPAXONE R 55 TYKERB 55 Phase 2a trial 55 Phase III randomized 54 DSMB 54 placebo controlled trials 54 virologic failure 54 bazedoxifene 54 muraglitazar 54 relapsed refractory multiple myeloma 54 multicentre 54 prospective randomized controlled 54 vicriviroc 54 multicenter clinical 54 Phase 1a 54 TELCYTA 54 subgroup analyzes 54 aflibercept 54 peginterferon alfa 2b 54 Phase IIb trial 53 Phase 2b trial 53 substudy 53 randomized placebo controlled 53 placebo controlled studies 53 dose escalation trial 53 randomized Phase III 53 DMARD 53 phase 2a 53 abatacept 53 prospective observational 53 Phase 2a clinical 53 dose cohorts 53 noninferiority 53 EORTC 52 Phase 1b trial 52 secondary efficacy endpoints 52 romidepsin 52 ocrelizumab 52 cetrorelix 52 sunitinib 52 Phase IIa clinical 52 metastatic renal cell carcinoma 52 TroVax 52 Phase IIa trial 52 multicenter randomized 52 PROMACTA 52 Phase III 51 confirmatory Phase III 51 RG# [001] 51 pazopanib 51 Arch Intern Med 51 unblinded 51 multicenter randomized double 51 ozarelix 51 mg QD 51 fondaparinux 51 vandetanib 51 Phase 1b 51 Monotherapy 51 Phase 2b 51 multiple ascending dose 51 SUTENT 51 Phase III clinical 51 nitazoxanide 51 BCX# 51 ofatumumab 51 dose regimens 51 mg kg dose 51 sitagliptin 51 LIALDA 51 mg BID 51 Phase 2b clinical 50 Phase 2a 50 ziprasidone 50 active comparator 50 tesmilifene 50 Phase IIb 50 randomized 50 clopidogrel 50 peginterferon 50 decitabine 50 nab paclitaxel 50 XGEVA 50 composite endpoint 50 ADHF 50 eniluracil 50 Phase Ib 50 randomized controlled clinical 50 FOLFIRI 50 nonresponders 50 dose escalation 50 dose escalation study

Back to home page